Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency

Y. Hasegawa, Tomonobu Hasegawa, T. Aso, S. Kotoh, O. Nose, Y. Ohyama, K. Araki, T. Tanaka, S. Saisyo, S. Yokoya, Y. Nishi, S. Miyamoto, N. Sasaki, F. Kurimoto, M. Stene, Y. Tsuchiya

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We have shown previously that serum insulin-like growth factor binding protein-3 (IGPBP-3) levels have good predictive value for complete, but not partial, growth hormone deficiency (GHD). In this study, we compare TGFBP-3 levels in short children previously divided into groups on the basis of their post-stimulation GH levels. Complete GHD (N = 59) included those children with peak post-stimulation GH < 5 μg/l. The partial GHD group (N = 49) had post-stimulation GH peaks of > 5 μg/l but < 10 μg/l. The normal children with short stature (N = 103) had post-stimulation GH peaks > 10 μg/l. Partial GHD and normal children with short stature also were divided into either low IGF-I or normal IGF-I subgroups. The clinical sensitivity of IGFBP-3 for complete GHD was 92%, whereas its sensitivity for partial GHD was 39%. For partial GHD, among those with low IGF-I (N = 19) 68% were also low for IGFBP-3, while 80% of those with normal IGF-I (N = 30) were also normal for IGFBP-3, The clinical specificity of IGFBP-3 for normal children with short stature was 69%. For these groups, among those with low TGF-I (N = 22) 73% also were low for IGFBP-3, while 80% of those with normal IGF-I (N = 81) also were normal for IGFBP-3. In addition, we tested whether IGFBP-3 can predict the response to GH treatment in prepubertal children by comparing pretreatment IGFBP-3 with the height gain achieved by 1 year of GH treatment. The incremental growth velocity during treatment correlated significantly with the pretreatment IGFBP-3 SD score (N = 46 r = -0.80, p < 0.005). The baseline IGFBP-3 so score for all subjects correlated (N = 171, r = 0.51 p < 0.0001) with height. These data suggest that IGFBP-3 may reflect GH secretion status in most children being evaluated for GHD and that a low pretreatment IGFBP-3 so score predicts improved growth during the first year of GH treatment.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalEuropean Journal of Endocrinology
Volume131
Issue number1
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Growth Hormone
Insulin-Like Growth Factor I
Therapeutics
Growth

ASJC Scopus subject areas

  • Endocrinology

Cite this

Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency. / Hasegawa, Y.; Hasegawa, Tomonobu; Aso, T.; Kotoh, S.; Nose, O.; Ohyama, Y.; Araki, K.; Tanaka, T.; Saisyo, S.; Yokoya, S.; Nishi, Y.; Miyamoto, S.; Sasaki, N.; Kurimoto, F.; Stene, M.; Tsuchiya, Y.

In: European Journal of Endocrinology, Vol. 131, No. 1, 1994, p. 27-32.

Research output: Contribution to journalArticle

Hasegawa, Y, Hasegawa, T, Aso, T, Kotoh, S, Nose, O, Ohyama, Y, Araki, K, Tanaka, T, Saisyo, S, Yokoya, S, Nishi, Y, Miyamoto, S, Sasaki, N, Kurimoto, F, Stene, M & Tsuchiya, Y 1994, 'Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency', European Journal of Endocrinology, vol. 131, no. 1, pp. 27-32.
Hasegawa, Y. ; Hasegawa, Tomonobu ; Aso, T. ; Kotoh, S. ; Nose, O. ; Ohyama, Y. ; Araki, K. ; Tanaka, T. ; Saisyo, S. ; Yokoya, S. ; Nishi, Y. ; Miyamoto, S. ; Sasaki, N. ; Kurimoto, F. ; Stene, M. ; Tsuchiya, Y. / Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency. In: European Journal of Endocrinology. 1994 ; Vol. 131, No. 1. pp. 27-32.
@article{6ba8a4b3b7834ce48fa7c9ee87383cc7,
title = "Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency",
abstract = "We have shown previously that serum insulin-like growth factor binding protein-3 (IGPBP-3) levels have good predictive value for complete, but not partial, growth hormone deficiency (GHD). In this study, we compare TGFBP-3 levels in short children previously divided into groups on the basis of their post-stimulation GH levels. Complete GHD (N = 59) included those children with peak post-stimulation GH < 5 μg/l. The partial GHD group (N = 49) had post-stimulation GH peaks of > 5 μg/l but < 10 μg/l. The normal children with short stature (N = 103) had post-stimulation GH peaks > 10 μg/l. Partial GHD and normal children with short stature also were divided into either low IGF-I or normal IGF-I subgroups. The clinical sensitivity of IGFBP-3 for complete GHD was 92{\%}, whereas its sensitivity for partial GHD was 39{\%}. For partial GHD, among those with low IGF-I (N = 19) 68{\%} were also low for IGFBP-3, while 80{\%} of those with normal IGF-I (N = 30) were also normal for IGFBP-3, The clinical specificity of IGFBP-3 for normal children with short stature was 69{\%}. For these groups, among those with low TGF-I (N = 22) 73{\%} also were low for IGFBP-3, while 80{\%} of those with normal IGF-I (N = 81) also were normal for IGFBP-3. In addition, we tested whether IGFBP-3 can predict the response to GH treatment in prepubertal children by comparing pretreatment IGFBP-3 with the height gain achieved by 1 year of GH treatment. The incremental growth velocity during treatment correlated significantly with the pretreatment IGFBP-3 SD score (N = 46 r = -0.80, p < 0.005). The baseline IGFBP-3 so score for all subjects correlated (N = 171, r = 0.51 p < 0.0001) with height. These data suggest that IGFBP-3 may reflect GH secretion status in most children being evaluated for GHD and that a low pretreatment IGFBP-3 so score predicts improved growth during the first year of GH treatment.",
author = "Y. Hasegawa and Tomonobu Hasegawa and T. Aso and S. Kotoh and O. Nose and Y. Ohyama and K. Araki and T. Tanaka and S. Saisyo and S. Yokoya and Y. Nishi and S. Miyamoto and N. Sasaki and F. Kurimoto and M. Stene and Y. Tsuchiya",
year = "1994",
language = "English",
volume = "131",
pages = "27--32",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency

AU - Hasegawa, Y.

AU - Hasegawa, Tomonobu

AU - Aso, T.

AU - Kotoh, S.

AU - Nose, O.

AU - Ohyama, Y.

AU - Araki, K.

AU - Tanaka, T.

AU - Saisyo, S.

AU - Yokoya, S.

AU - Nishi, Y.

AU - Miyamoto, S.

AU - Sasaki, N.

AU - Kurimoto, F.

AU - Stene, M.

AU - Tsuchiya, Y.

PY - 1994

Y1 - 1994

N2 - We have shown previously that serum insulin-like growth factor binding protein-3 (IGPBP-3) levels have good predictive value for complete, but not partial, growth hormone deficiency (GHD). In this study, we compare TGFBP-3 levels in short children previously divided into groups on the basis of their post-stimulation GH levels. Complete GHD (N = 59) included those children with peak post-stimulation GH < 5 μg/l. The partial GHD group (N = 49) had post-stimulation GH peaks of > 5 μg/l but < 10 μg/l. The normal children with short stature (N = 103) had post-stimulation GH peaks > 10 μg/l. Partial GHD and normal children with short stature also were divided into either low IGF-I or normal IGF-I subgroups. The clinical sensitivity of IGFBP-3 for complete GHD was 92%, whereas its sensitivity for partial GHD was 39%. For partial GHD, among those with low IGF-I (N = 19) 68% were also low for IGFBP-3, while 80% of those with normal IGF-I (N = 30) were also normal for IGFBP-3, The clinical specificity of IGFBP-3 for normal children with short stature was 69%. For these groups, among those with low TGF-I (N = 22) 73% also were low for IGFBP-3, while 80% of those with normal IGF-I (N = 81) also were normal for IGFBP-3. In addition, we tested whether IGFBP-3 can predict the response to GH treatment in prepubertal children by comparing pretreatment IGFBP-3 with the height gain achieved by 1 year of GH treatment. The incremental growth velocity during treatment correlated significantly with the pretreatment IGFBP-3 SD score (N = 46 r = -0.80, p < 0.005). The baseline IGFBP-3 so score for all subjects correlated (N = 171, r = 0.51 p < 0.0001) with height. These data suggest that IGFBP-3 may reflect GH secretion status in most children being evaluated for GHD and that a low pretreatment IGFBP-3 so score predicts improved growth during the first year of GH treatment.

AB - We have shown previously that serum insulin-like growth factor binding protein-3 (IGPBP-3) levels have good predictive value for complete, but not partial, growth hormone deficiency (GHD). In this study, we compare TGFBP-3 levels in short children previously divided into groups on the basis of their post-stimulation GH levels. Complete GHD (N = 59) included those children with peak post-stimulation GH < 5 μg/l. The partial GHD group (N = 49) had post-stimulation GH peaks of > 5 μg/l but < 10 μg/l. The normal children with short stature (N = 103) had post-stimulation GH peaks > 10 μg/l. Partial GHD and normal children with short stature also were divided into either low IGF-I or normal IGF-I subgroups. The clinical sensitivity of IGFBP-3 for complete GHD was 92%, whereas its sensitivity for partial GHD was 39%. For partial GHD, among those with low IGF-I (N = 19) 68% were also low for IGFBP-3, while 80% of those with normal IGF-I (N = 30) were also normal for IGFBP-3, The clinical specificity of IGFBP-3 for normal children with short stature was 69%. For these groups, among those with low TGF-I (N = 22) 73% also were low for IGFBP-3, while 80% of those with normal IGF-I (N = 81) also were normal for IGFBP-3. In addition, we tested whether IGFBP-3 can predict the response to GH treatment in prepubertal children by comparing pretreatment IGFBP-3 with the height gain achieved by 1 year of GH treatment. The incremental growth velocity during treatment correlated significantly with the pretreatment IGFBP-3 SD score (N = 46 r = -0.80, p < 0.005). The baseline IGFBP-3 so score for all subjects correlated (N = 171, r = 0.51 p < 0.0001) with height. These data suggest that IGFBP-3 may reflect GH secretion status in most children being evaluated for GHD and that a low pretreatment IGFBP-3 so score predicts improved growth during the first year of GH treatment.

UR - http://www.scopus.com/inward/record.url?scp=0028301611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028301611&partnerID=8YFLogxK

M3 - Article

VL - 131

SP - 27

EP - 32

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -